FDA Policy for REMS Reqmts during COVID-19

Health Care, Pharma Industry, Strategic Planning

FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.

Read the Policy now

 

 

Related Education Resources.

All Resources

COVID-19’s Impact on the Supply Chain in Asia-Pacific

Topics: COVID-19, Supply Chain

Webinar

Free

GCSG sponsored study on INVESTIGATIVE SITE Receptivity to Direct-to-Patient Shipment in Clinical Trials

Topic: Direct-to-Patient

White Paper

Members

EAP 104: EAP Communication and Stakeholder Management

Topics: Additional Concepts, Closeout, EAP, Execution, Forecasting / Planning

Presentation

Members

Become a member

Global Clinical Supplies Group

Join GCSG for full access...

to our educational resources, conference materials and our directory of more than 480 Clinical Supply colleagues. Experience the culture of collaboration, It only takes approximately 3 minutes 22 seconds.

Please note that membership is included and FREE of charge when you sign up for an event.

Join Renew